The patient with an overactive bladder--symptoms and quality-of-life issues.
about
Which anticholinergic drug for overactive bladder symptoms in adultsAnticholinergic drugs versus placebo for overactive bladder syndrome in adultsWhich anticholinergic drug for overactive bladder symptoms in adultsHow widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence studyImpact of urinary incontinence on the quality of life of women.Urinary incontinence.Evaluation and treatment of the overactive bladder.Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review.Botulinum toxin A should not be first-line therapy for overactive bladder.Psychometric Properties of the Korean Version of the Overactive Bladder Questionnaire (OAB-q) in a Korean Population.Sacral neuromodulation and refractory overactive bladder: an emerging tool for an old problem.Absolute bioavailability of imidafenacin after oral administration to healthy subjectsBotulinum toxin for treatment of urinary incontinence due to detrusor overactivity: a systematic review of effectiveness and adverse effects.Neurotoxin treatments for urinary incontinence in subjects with spinal cord injury or multiple sclerosis: a systematic review of effectiveness and adverse effects.Correlation between clinical presentation and urodynamic findings in women attending urogynecology clinic.Onabotulinum toxin A for the treatment of neurogenic detrusor overactivity due to spinal cord injury or multiple sclerosis.Antimuscarinic use among individuals with urinary incontinence who reside in long-term care facilities.Real-world characteristics of elderly patients with overactive bladder in the United States.Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system.Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients.Tolterodine: as effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder.Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder.Effect of itraconazole on the pharmacokinetics of imidafenacin in healthy subjects.The "bother" of urinary incontinence.What is the success of drug treatment in urge urinary incontinence? What should be measured?The therapeutic effects of repeated detrusor injections between 200 or 300 units of onabotulinumtoxinA in chronic spinal cord injured patients.Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder.Comorbidities associated with bladder dysfunction.Medical visits among adults with symptoms commonly associated with an overactive bladder.The pharmacotherapy of overactive bladder.The relationship between overactive bladder and sexual activity in women.The impact of the overactive bladder on health-related utility and quality of life.Clinical Efficacy of Solifenacin in the Management of Diabetes Mellitus-Associated Versus Idiopathic Overactive Bladder Symptoms: A Multicenter Prospective Study.
P2860
Q24203880-B253C1CB-C9CA-4A23-AB62-7C651AD98804Q24243870-AE072160-CCDF-4A89-B7B9-587725BE28D3Q24246651-E891FD6E-008B-4EBB-84B7-231040FD186FQ28202479-2A295BEA-C138-40BB-9683-A9865A53B48DQ33689065-A23B45E0-F94B-49D1-8FB9-7C832DB2BB56Q33941954-5FE9BD06-0833-4ED1-9B7D-114833CF571BQ34778719-84804177-D566-4B77-AD20-C3A57EE960EEQ34950386-5875B9BF-525D-47F8-826B-A980AC3829BEQ35042443-6D9B77D3-A4EA-4AA9-884A-0E0B9A43C280Q36092237-DE723C9B-58EA-438D-9EBB-770628D73214Q36099913-BBB058CD-0E5F-443E-8586-99B2AAEC2816Q36535862-FF9E438E-8354-40E5-9EB0-A8A352E4F9ADQ36799110-7897542A-6C1B-4B6C-9B3A-E1ADF9FB5363Q36932034-64745ED7-52ED-4C1D-AA6D-82DC17E0FF31Q37634783-66D82A04-EE9D-43FB-A944-69E45B131E45Q38031284-A44D9043-786A-4049-B230-7ED4BAA76F65Q38128787-CCA61FA8-D730-4D2C-94A2-F31566ED8EFBQ38819707-05954D75-0A9F-4B32-9539-F5963FF87D76Q42651945-55F85CE8-290B-44CD-BB8B-6B5D2EAE4C5DQ44004623-F1C5254D-7251-43C4-8C84-D6B7C69F1989Q44024674-DF8E40FB-1F5E-4A71-8D82-EAA7909F9CA3Q44756641-B0409A84-65D5-45DE-8A17-DEC465FFCC4EQ46792449-91ACCA69-327B-4825-B328-3D382DB053EFQ48086124-54D53F1A-0AD5-48C1-BE58-7392C5CDD437Q48216850-70C6F3B0-E14A-473A-B017-28FAF2D799B3Q48279466-8885D077-B5E1-4A05-A47C-C699989382BDQ48304126-76592E49-C437-4E88-B61C-BC4E15AE1187Q50728227-97C56F88-72CC-4FBD-901A-12D99969E7DFQ50776936-4FEF2126-3DE7-416F-BB20-8464E77E71C6Q51759941-8A7D3EE0-6285-4E89-B827-E3905F3667B8Q51816379-39E45C37-01BC-40C4-87DE-265520694E0BQ51917722-78D1E760-9D9D-48C7-BA8C-F628DB34B374Q52612613-FF4A023C-B919-4963-AA83-E3BE25939D81
P2860
The patient with an overactive bladder--symptoms and quality-of-life issues.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
The patient with an overactive bladder--symptoms and quality-of-life issues.
@en
type
label
The patient with an overactive bladder--symptoms and quality-of-life issues.
@en
prefLabel
The patient with an overactive bladder--symptoms and quality-of-life issues.
@en
P1433
P1476
The patient with an overactive bladder--symptoms and quality-of-life issues.
@en
P2093
P304
18-22; discussion 23-4
P356
10.1016/S0090-4295(97)00580-3
P407
P433
P577
1997-12-01T00:00:00Z